

Consent to certain actions for the purposes of the Initial Enforcement Order made by the Competition and Markets Authority ('CMA') on 24 March 2017

Completed acquisition by GLO Dutch Bidco B.V. of Mallinckrodt Netherlands Holdings B.V. and Mallinckrodt Nuclear Medicine LLC

We refer to your submission of 24 March 2017 requesting that the CMA consents to derogations to the Initial Enforcement Order of 24 March 2017 (the Initial Order). The terms defined in the Initial Order have the same meaning in this letter.

Under the Initial Order, except with the prior written consent of the CMA, GLO BidCo S.å r.l., IBA Pharma SA, GLO Dutch Bidco B.V. and Mallinckrodt Netherlands Holdings BV shall not, during the specified period, take any action which might prejudice a reference of the transaction under section 22 of the Act or impede the taking of any remedial action following such reference.

After due consideration of your request for derogations from the Initial Order, based on the information received from you and in the particular circumstances of this case, GLO BidCo S.å r.l, IBA Pharma SA, GLO Dutch Bidco B.V. and Mallinckrodt Netherlands Holdings BV may carry out the following actions.

Paragraphs 1 to 11 of the Initial Order

Given that the businesses of GLO BidCo S.å r.l and IBA Pharma SA, and the businesses of a number of subsidiaries of GLO BidCo S.å r.l, IBA Pharma SA, GLO Dutch Bidco B.V. and Mallinckrodt Netherlands Holdings BV have no connection at all with the UK market, in order to allow the integration of those businesses, the following companies are released from the requirements of the Initial Order:

a)	The following	subsidiaries	of GLO	Dutch	Ridco	B./	/ :
----	---------------	--------------	--------	-------	-------	-----	------------

- [※]
- [%]
- [%]
- [%]

• [%]		
• [%]		
• [%]		
• [%]		
• [%]		

b) GLO BidCo S.å r.l.



d) IBA Pharma SA.

e) The following subsidiaries of IBA Pharma SA:



- [%]
- [%]
- [%]
- [%]
- [%]
- [%]
- [%]
- [%]
- [%]
- [%]